We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Monthly Production Capacity: 1000KG/DAYS
Packaging Information: foil bag/bottle
Delivery Lead Time: immediate delivery
Sample Provided: yes
Payment Terms: T/T,LC
Product name: Doravirine ( MK-1439)
Purity: 99% min
Synonym: MK-1439
CAS NO.: 1338225-97-0
Molecular Formula: Doravirine ( MK-1439) has the molecular formula being C17H11ClF3N5O3
Molecular weight: Doravirine ( MK-1439) has the molecular weight being 425.7491496
Product quality: our professional technicians have studied the characteristic specifications of Doravirine ( MK-1439)(1338225-97-0 ), including appearance, identification, assay, related substances, residual solvents and so on. For more detailed COA, please contact us. Email: marketing@chemvon.com
Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor,for use in the treatment of HIV/AIDS. Doravirine demonstrated robust antiviral activity and good tolerability in a small clinical study of 7-day monotherapy reported at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013. Doravirine appeared safe and generally well-tolerated with most adverse events being mild-to-moderate
Two years of qualification
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
